Eptinezumab for migraine prevention in patients 50 years or older.

Vincent MartinCristina TassorelliAnders EttrupJoe HirmanRoger Cady

Published in: Acta neurologica Scandinavica (2022)

Treatment with eptinezumab was efficacious, tolerable, and safe in patients ≥50 years with EM or CM, congruent with results from the overall study population.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
physical activity
patient reported outcomes